Upgrading mRNA from an "expression tool" to a programmable therapeutic system
From cap, UTR, coding sequence and poly(A) to nucleoside modifications and structural elements, RNACure applies a "component optimization + combinatorial rules" molecular engineering approach to systematically reshape mRNA expression kinetics, immune behavior, and tissue/cell specificity.
The evolution from mRNA 1.0 to 5.0 is not merely an improvement in expression efficiency—it is a shift from "can express" to "designable, controllable, and reproducible" therapeutic systems. RNACure builds a reusable molecular capability foundation around three themes: longer expression duration, more precise tissue and cell specificity, and stricter safety and control boundaries. Driven by continuous innovation and clinical translation, we are expanding mRNA from infectious disease prevention into rare and chronic disease treatment, immuno-oncology, and CGT-related applications.
- Meets short-window high-expression needs
- Validates clinical feasibility and safety of mRNA
- ~3–5× improvement in expression efficiency
- Half-life extended to 24–48 hours
- Equivalent or stronger effect at lower doses
- Half-life ~3 days, on par with circRNA
- Cell-differential expression capability at the RNA level
- Half-life up to ~1 month for long-acting therapy
- Breakthrough tissue-specific expression (liver, myocardium, bone marrow, etc.)
- Precise targeting with minimized off-target effects
- AAV-level long-term expression under controlled safety boundaries
- Upgrade from vaccine platform to CGT technology pillar
- Supports systematic implementation of complex gene therapy regimens
